Karen Anthony

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study

Sebahattin Çirak, Virginia Arechavala‐Gomeza, Michela Guglieri et al. · The Lancet · 2011 · 862 citations · Full text

Medicine, Neurology, Pharmacotherapy +13

Attenuation of Insulin-Evoked Responses in Brain Networks Controlling Appetite and Reward in Insulin Resistance

Karen Anthony, Laurence Reed, Joel Dunn et al. · Diabetes · 2006 · 192 citations · Full text

Medicine, Endocrinology, Neuroscience +16

Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials

Karen Anthony, Sebahattin Çirak, Silvia Torelli et al. · Brain · 2011 · 150 citations · Full text

Life Sciences, Genetics, Molecular Genetics +15

A Novel Morpholino Oligomer Targeting ISS-N1 Improves Rescue of Severe Spinal Muscular Atrophy Transgenic Mice

Haiyan Zhou, Narinder Janghra, Chalermchai Mitrpant et al. · Human Gene Therapy · 2013 · 123 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17

Biochemical Characterization of Patients With In-Frame or Out-of-Frame<i>DMD</i>Deletions Pertinent to Exon 44 or 45 Skipping

Karen Anthony, Virginia Arechavala‐Gomeza, Valeria Ricotti et al. · JAMA Neurology · 2013 · 108 citations

Life Sciences, Molecular Biology, Molecular Genetics +14